

29th May, 2015

To,
The Secretary,
National Stock Exchange
Plot No.C/1G Block,
Bandra-Kurla Complex
Bandra (East)
Mumbai- 400051

SUBJECT: BOARD MEETING OUTCOME

Dear Sir,

The Board meeting of the company was held on 29th May, 2015 at the registered office of the Company at 3.30 p.m. The Board has considered and approved the followings:

1. Pursuant to cl. 41 of the Listing Agreement read with the Companies Act, 2013, audited accounts of the company for the year ended 31/3/2015;
2. Declared Final Dividend at the rate of 50% i.e. Re. 0.50 per share;
3. Sale of Step Down subsidiary "Surgimed Pharma Limited" located at Kenya;
4. Due to ill health Mr. G.G Desai resigned from the Board;
5. Re-appointment of the Statutory Auditor of the Company;
6. Appointment of Secretarial Auditor for the financial year 2015-2016;
7. Appointment of Internal Auditor of the Company for the financial year 2015-16;
8. Adopted the Secretarial Audit report, Board report, Auditors report & Notice of the forthcoming Annual General Meeting;
9. Code of Prevention and Prohibition of Insider Trading in Securities of the Company under SEBI (Prohibition of Insider Trading) Regulation, 2015.

Please acknowledge and take on record the same.

Thanking you,

For **BLISS GVS PHARMA LIMITED**


VIPUL B. THAKKAR
GM-CORPORATE FINANCE

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

BLISS GVS PHARMA LIMITED
 Regd Office-102, Hyde Park, Sakivihar Road,
 Andheri (East), Mumbai - 400 072
AUDITED FINANCIAL RESULTS
FOR THE QUARTER / YEAR ENDED 31.03.2015

PART - I

(Rs. in Lacs)

SR. NO.	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED
		31.03.2015 (AUDITED)*	31.12.2014 (UNAUDITED)						
1	INCOME FROM OPERATIONS (a) NET SALES (NET OF EXCISE DUTY) (b) OTHER OPERATING INCOME	6,796.32 68.51	8,413.00 116.50	5,373.14 120.17	30,945.89 356.28	28,349.25 473.82	40,307.34 406.10	33,973.26 490.95	
	TOTAL INCOME FROM OPERATIONS(NET)	6,864.83	8,529.50	5,493.31	31,302.17	28,823.07	40,713.44	34,464.21	
2	EXPENSES a) CONSUMPTION OF RAW MATERIALS b) PURCHASE OF TRADED GOODS c) (INCREASE)/DECREASE IN STOCK IN TRADE d) EMPLOYEE BENEFIT EXPENSES e) DEPRECIATION / AMORTISATION f) OTHER EXPENDITURE TOTAL EXPENSES	2,946.33 113.10 469.38 145.07 2,040.08 5,713.96	4,041.61 -150.56 458.74 131.35 1,786.92 6,268.06	2,969.99 529.50 -369.38 340.48 71.57 1,363.94 4,906.09	13,784.13 90.32 248.27 1,736.08 507.83 6,823.95 23,190.58	13,517.82 1,030.40 60.57 1,292.61 446.16 6,314.46 22,662.02	16,456.36 933.42 364.87 2,942.90 1,129.62 9,671.97 31,499.14	15,554.08 1,551.65 (42.67) 2,346.28 1,068.18 7,932.83 28,410.35	
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COST & EXCEPTIONAL ITEMS (1-2)	1,150.87	2,261.44	587.21	8,111.59	6,161.05	9,214.30	6,053.86	
4	OTHER INCOME	213.17	850.05	145.68	2,135.03	3,012.42	2,028.86	2,800.19	
5	PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COST (3+4)	1,364.04	3,111.49	732.89	10,246.63	9,173.47	11,243.16	8,854.05	
6	FINANCE COST	296.42	349.61	309.44	1,121.18	943.63	1,641.24	1,798.23	
7	PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5-6)	1,067.61	2,761.88	423.45	9,125.45	8,229.84	9,601.92	7,055.82	
8	EXCEPTIONAL ITEMS								
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7 - 8)	1,067.61	2,761.88	423.45	9,125.45	8,229.84	9,601.92	7,055.82	
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	421.51	962.62	272.00	3,123.90	2,837.19	3,462.58	2,952.67	
11	NET PROFIT FOR THE PERIOD (9 - 10)	646.10	1,799.26	151.45	6,001.55	5,392.65	6,139.34	4,103.15	
12	MINORITY INTEREST						(148.37)	(3.98)	
13	NET PROFIT AFTER TAX & MINORITY INTEREST (11-12)	646.10	1,799.26	151.45	6,001.55	5,392.65	5,990.97	4,099.17	
14	PAID - UP EQUITY CAPITAL	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)				35,787.14	30,452.64	32,676.83	27,656.65	
16	BASIC AND DILUTED EPS (NOT ANNUALISED)	0.63	1.74	0.15	5.82	5.23	5.81	3.97	

PART - II

PARTICULARS		STANDALONE						CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED			
		31.03.2015 (AUDITED)*	31.12.2014 (UNAUDITED)						31.03.2014 (AUDITED)	31.03.2015 (AUDITED)	31.03.2014 (AUDITED)
A	PARTICULARS OF SHAREHOLDING										
1	AGGREGATE OF NON-PROMOTER SHAREHOLDING - NO. OF SHARES (FACE VALUE RS.1/- EACH) - PERCENTAGE OF SHAREHOLDING (%)	36156842 35.05	36156842 35.05	36156842 35.05	36156842 35.05	36156842 35.05	36156842 35.05	36156842 35.05	36156842 35.05	36156842 35.05	
2	PROMOTER AND PROMOTER GROUP SHAREHOLDING A) PLEDGE/ ENCUMBERED - NO. OF SHARES (FACE VALUE RE.1/- EACH) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY) B) NON - ENCUMBERED - NO. OF SHARES (FACE VALUE RE.1/- EACH) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY)	66989830 100.00 64.95	66989830 100.00 64.95	66989830 100.00 64.95	66989830 100.00 64.95	66989830 100.00 64.95	66989830 100.00 64.95	66989830 100.00 64.95	66989830 100.00 64.95	66989830 100.00 64.95	
B	INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the quarter Disposed off during the quarter REMAINING UNSOLVED AT THE END OF THE QUARTER	- 10 2 8									
	Particulars	Quarter ended 31 March 2015									

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2015

(Rs. In Lacs)

	Particulars	STANDALONE		CONSOLIDATED	
		Mar-15	Mar-14	Mar-15	Mar-14
I.	EQUITY AND LIABILITIES				
1	SHAREHOLDERS' FUNDS :				
	(i) Share Capital	1,031.47	1,031.47	1,031.47	1,031.47
	(ii) Reserves and Surplus	35,787.14	30,452.64	32,676.83	27,656.65
	(iii) Money received against share warrants				
	Sub-total - Shareholders' funds	36,818.61	31,484.11	33,708.30	28,688.12
2	Minority Interest	-	-	1,489.18	1,016.26
3	Non-Current liabilities				
	(i) Long term Borrowings	3,020.95	4,513.54	5,725.81	8,758.83
	(ii) Deferred tax liabilities (Net)	715.30	619.80	885.94	695.79
	(iv) Long term provisions	139.85	110.33	139.85	110.33
	Sub-total - Non-current liabilities	3,876.10	5,243.67	6,751.60	9,564.95
4	Current liabilities				
	(i) Short term Borrowings	2,837.62	2,314.16	6,104.21	5,704.90
	(ii) Trade payables	5,046.72	5,898.97	8,033.39	8,235.44
	(iii) Other current liabilities	3,913.46	2,851.53	7,030.05	4,211.63
	(iv) Short term provisions	3,007.62	847.01	3,100.09	857.26
	Sub-total -current liabilities	14,805.42	11,911.67	24,267.74	19,009.23
	Total.....	55,500.13	48,639.45	66,216.82	58,278.56
II.	ASSETS				
1	Non-current assets				
	(a) Fixed Assets	8,150.39	5,783.71	16,062.00	14,394.36
	(b) Goodwill on Consolidation	-	-	7,376.00	7,369.64
	(b) Non-current Investments	1,922.63	1,922.53	1.01	1.01
	(d) Long term loans and advances	10,135.08	10,917.86	1,026.79	1,201.57
	(e) Other non current assets	43.26	142.37	43.26	142.36
	Sub-total - Non-current assets	20,251.36	18,766.47	24,509.06	23,108.94
2	Current assets				
	(b) Inventories	2,251.83	2,122.89	3,370.00	3,253.04
	(c) Trade receivables	21,061.21	18,353.25	24,746.94	21,502.59
	(d) Cash and Bank balances	4,736.77	7,412.07	5,728.93	8,037.21
	(e) Short term loans and advances	6,133.62	1,252.04	7,470.88	2,067.83
	(f) Other current assets	1,065.34	732.73	391.01	308.95
	Sub-total - Current assets	35,248.77	29,872.98	41,707.76	35,169.62
	Total.....	55,500.13	48,639.45	66,216.82	58,278.56

NOTES:-

1. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.
2. THE CONSOLIDATED RESULTS INCLUDES THE AUDITED FINANCIAL RESULTS OF PARENT COMPANY, THE SUBSIDIARIES NAMELY BLISS GVS INTERNATIONAL PTE LTD (100% HOLDING), BLISS INDASI LIFE SCIENCES PVT LTD (51% HOLDING), BLISS GVS CLINIC HEALTHCARE PTE LTD (100% HOLDING), KREMOUNT PHARMA PVT. LTD. (70% HOLDING), LIFEON LABS PVT LTD (51%), ASTERISK LIFESCIENCES LTD (100%) & THEIR STEP DOWN SUBSIDIARIES
3. TAX EXPENSES FOR THE QUARTER AND YEAR ENDED MARCH 31, 2015 INCLUDES SHORT PROVISION FOR EARLIER YEARS RS. 41.90 LACS AND THE QUARTER AND YEAR ENDED MARCH 31, 2014 INCLUDES SHORT PROVISION OF EARLIER YEARS OF RS. 170.00 LACS.
4. THE BOARD HAS RECOMMENDED A DIVIDEND OF 50% I.e RS. 0.50 PER EQUITY SHARE FOR THE YEAR ENDED 31ST MARCH 2015
- *5. THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2015 & 2014 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR AND THE YEAR TO DATE PUBLISHED RESULTS FOR THE NINE MONTHS ENDED DECEMBER 31, 2014 & 2013.
6. THE COMPANY HAS RECOMPUTED THE DEPRECIATION BASED ON THE USEFUL LIFE OF THE ASSETS AS PER ACCOUNTING POLICY . THIS HAS RESULTED IN ADDITIONAL CHARGE OF DEPRECIATION OF RS. 126.45 LACS FOR THE YEAR ENDED 31ST MARCH, 2015. FURTHER, AS PER TRANSITIONAL PROVISION OF THE COMPANIES ACT 2013, THE COMPANY HAS ADJUSTED THE WRITTEN DOWN VALUE OF RS. 7.06 LACS (NET OF DEFERRED TAX OF RS. 2.40 LACS)IN THE OPENING BALANCE OF SURPLUS IN PROFIT AND LOSS.
7. PREVIOUS YEAR/PERIOD FIGURES ARE REGROUPED /REARRANGED WHEREVER NECESSARY.
8. THE ABOVE RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON MAY 29TH 2015

PLACE : MUMBAI
DATE : 29 TH MAY 2015

FOR BLISS GVS PHARMA LTD

SD /-
S.N.KAMATH
MANAGING DIRECTOR